Non-Hodgkin Lymphoma Therapeutics Market Players:
- AbbVie, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GSK plc.
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- SIRPant Immunotherapeutics Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of non-hodgkin lymphoma therapeutics is assessed at USD 11.88 billion.
The global non-hodgkin lymphoma therapeutics market size surpassed USD 11.13 billion in 2025 and is projected to witness a CAGR of more than 7.5%, crossing USD 22.94 billion revenue by 2035.
North America non-hodgkin lymphoma therapeutics market will hold more than 30% share by 2035, fueled by adoption of AI and well-regulated frameworks in healthcare.
Key players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Merck & Co., Inc., Gilead Sciences, Inc., Amgen Inc., Celgene Corporation (Bristol-Myers Squibb), AbbVie Inc., Takeda Pharmaceutical Company Limited.
